Pivot-02: Preliminary safety, efficacy and biomarker results from the Phase 1/2 study of CD-122-biased agonist NKTR-214 plus nivolumab in patients with locally advanced/metastatic solid tumors

被引：0

作者：

Diab, Adi ^{[1
]}

Tannir, Nizar ^{[1
]}

Cho, Daniel ^{[2
]}

Papadimitrakopoulou, Vali ^{[1
]}

Bernatchez, Chantale ^{[1
]}

Haymaker, Cara ^{[1
]}

Bentebibel, Salah Eddine ^{[1
]}

Curti, Brendan ^{[3
,4
]}

Wong, Michael ^{[1
]}

Tykodi, Scott ^{[5
,6
]}

Puzanoff, Igor ^{[7
]}

Smalberg, Ira ^{[7
]}

Gergel, Ivan ^{[8
]}

Tagliaferri, Mary ^{[8
]}

Zalevsky, Jonathan ^{[8
]}

Hoch, Ute ^{[8
]}

Aung, Sandra ^{[8
]}

Imperiale, Michael ^{[8
]}

Clemens, Wendy ^{[9
]}

Kluger, Harriet ^{[10
]}

Hurwitz, Michael ^{[10
]}

Hwu, Patrick ^{[1
]}

Sznol, Mario ^{[10
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] NYU Med Oncol Associates, New York, NY USA

[3] Providence Canc Ctr, Portland, OR USA

[4] Earle A Chiles Res Inst, Portland, OR USA

[5] Univ Washington, Seattle, WA 98195 USA

[6] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[7] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[8] Nektar Therapeut, San Francisco, CA USA

[9] Bristol Myers Squibb, Lawrence Township, NJ USA

[10] Yale Sch Med, New Haven, CT USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O20

引用

页数：1

共 50 条

[41] Phase 1b/2 study to assess the safety, tolerability, and clinical activity of BGB-290 in combination with temozolomide in patients with locally advanced or metastatic solid tumors
Johnson, M.
Benson, B.
Wei, R.
Brachmann, R.
Galsky, M. D.
ANNALS OF ONCOLOGY, 2017, 28
[42] Preliminary safety and efficacy data from a phase 1/2 study of epacadostat (INCB024360) in combination with pembrolizumab in patients with advanced/metastatic melanoma
Gajewski, Thomas F.
Hamid, Omid
Smith, David C.
Bauer, Todd M.
Wasser, Jeffrey S.
Luke, Jason J.
Balmanoukian, Ani S.
Kaufman, David R.
Zhao, Yufan
Maleski, Janet
Leopold, Lance
Gangadhar, Tara C.
JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
[43] SAFETY AND EFFICACY RESULTS FROM A PHASE 1/1B STUDY OF INTRATUMORAL MK-4621, A RETINOIC ACID-INDUCIBLE GENE I (RIG-I) AGONIST, PLUS INTRAVENOUS PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
Moreno, Victor
Gaudy-Marqueste, Caroline
Wermke, Martin
Italiano, Antoine
Romano, Emanuela
Marabelle, Aurelien
Connors, Emilee
Zhou, Heng
Dobrenkov, Konstantin
Chartash, Elliot
Calvo, Emiliano
Calvo Aller, Emiliano
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A474 - A475
[44] Re: Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results from a Phase 1/2 Open-Label Study Editorial Comment
Chang, Sam S.
JOURNAL OF UROLOGY, 2018, 199 (05) : 1110 - 1110
[45] LuMIERE: A phase 1/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of 177Lu-FAP-2286 in patients with advanced or metastatic solid tumors
McConathy, Jonathan
Dhawan, Mallika
Goenka, Ajit H.
Lim, Emerson A.
Menda, Yusuf
Chasen, Beth
Khushman, Moh'd
Mintz, Akiva
Zakharia, Yousef
Sunderland, John J.
Bowles, Owen
Xiao, Jim
Simmons, Andrew D.
Wride, Kenton
Enke, Aaron
Hope, Thomas A.
CANCER RESEARCH, 2022, 82 (12)
[46] Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanoma
Sacco, Joseph J.
Harrington, Kevin Joseph
Olsson-Brown, Anna
Chan, Tze Y.
Nenclares, Pablo
Leslie, Isla
Bommareddy, Praveen
Kalbasi, Alireza
Xie, Ben
Mishal, Moran
Cohan, David Michael
Skolariki, Aglaia
Middleton, Mark R.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[47] Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study
Moore, Kathleen N.
Sabanathan, Dhanusha
Du, Yiqun
Duan, Huaxin
Li, Xiumin
Wang, Feng
Marathe, Omkar
Yang, Hua
Makker, Vicky
Growdon, Whitfield
Coward, Jim
Zhao, Peng
Liu, Liming
Shi, Rong
Liu, Shengxue
Gu, Wei
Qiu, Yang
Zhu, Zhongyuan
Zhang, Jian
Hamilton, Erika P.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[48] Efficacy and safety of lucitanib plus nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO).
Patel, Manish R.
Makker, Vicky
Oaknin, Ana
Pignata, Sandro
Jenniskens Backes, Floor
Gonzalez Martin, Antonio
Nassef Eskander, Ramez
Pothuri, Bhavana
Richardson, Debra L.
Alvarez Secord, Angeles
Van Nieuwenhuysen, Els
Liu, Joyce F.
Musa, Fernanda
Penson, Richard T.
Wride, Kenton
Lepley, Denise M.
Dusek, Rachel
Cameron, Teresa
Hamilton, Erika P.
Concin, Nicole
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[49] Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors
Day, D.
Ganju, V.
Chung, K.
Si, L.
Mao, L.
Aghmesheh, M.
Hoyer, R.
Brewin, K.
Zeng, S.
Lu, Q.
Jiang, C.
Ren, F.
Wu, X.
Guo, J.
ANNALS OF ONCOLOGY, 2023, 34 : S625 - S625
[50] 177Lu-FAP-2286 in patients with advanced or metastatic solid tumors: Initial data from a phase 1/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumor activity (LuMIERE)
McConathy, Jonathan
Dhawan, Mallika
Goenka, Ajit
Moy, Ryan
Menda, Yusuf
Chasen, Beth
Khushman, Moh'd
Mintz, Akiva
Zakharia, Yousef
Sunderland, John
Bowles, Owen
Xiao, Jim
Simmons, Andrew
Wride, Kenton
Enke, Aaron
Hope, Thomas
JOURNAL OF NUCLEAR MEDICINE, 2022, 63

← 1 2 3 4 5 →